Multidrug resistance is frequently detected in haematological malignancies and in acute leukaemias with a poor prognosis. In the last few years, several reports seem to suggest that the new anthracycline derivative idarubicin and the anthraquinone mitoxantrone have some advantages in the management of untreated or relapsed acute leukaemias compared with older anthracyclines. This could be due to a different interaction of these drugs with multidrug resistance. To evaluate this possibility, we compared the activity of doxorubicin (DOXO), epirubicin (EPI), idarubicin (IDA) and mitoxantrone (MITO) on a murine, multidrug resistant, leukaemic cell line (P-388/Dx) cultured in vitro. id50 of IDA and MITO was in the ng range whereas that of DOXO and EPI was in the μg range. Moreover, IDA has a resistance index of 50 whereas DOXO has one of 250. Verapamil is able to almost completely abolish the resistance to IDA. Efflux experiments confirm that verapamil increases IDA intracellular concentration. IDA and MITO appear to be less involved in multidrug resistance than older anthracyclines.
|Autori interni:||TESTI, ROSSANA|
|Autori:||TESTI R; MATTII L; DI SIMONE D; ZACCARO L; MALVALDI G; GRASSI B; PETRINI M|
|Titolo:||EVALUATION OF RESISTANCE INDEX OF SEVERAL ANTICANCER AGENTS ON PARENTAL AND RESISTANT P-388 CELL LINES|
|Anno del prodotto:||1995|
|Digital Object Identifier (DOI):||10.1016/0145-2126(94)00157-6|
|Appare nelle tipologie:||1.1 Articolo in rivista|